Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282828 · ClinicalTrials.gov registry record · Phase 4
Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 397
- Enrollment target
NCT00282828: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00282828 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 397 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (23% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00282828, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 397 participants
- Enrollment target
Study Summary
This study will compare the effectiveness of either adding clonazepam or placebo to standard treatment or switching to venlafaxine in treating generalized social anxiety disorder in individuals who have not responded to treatment with sertraline.
Primary Outcome
The Liebowitz Social Anxiety Scale (LSAS) is a 24-item scale assessing fear and avoidance in social and performance situations; it is widely used in studies of pharmacological treatment of Generalized Social Anxiety Disorder (GSAD). Scores on the LSAS range from 0 to 144, with higher scores indicating greater pathology.
Interventions
- DRUG Placebo
- DRUG Sertraline
- DRUG Clonazepam
- DRUG Venlafaxine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 397 participants |
| Start Date | 2006-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
What the finished NCT00282828 record still lists
NCT00282828 is an interventional study that assigns participants to a tested intervention. The registered 397 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (23% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00282828 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00282828 about?
NCT00282828 is a clinical study titled "Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder". This study will compare the effectiveness of either adding clonazepam or placebo to standard treatment or switching to venlafaxine in treating generalized social anxiety disorder in individuals who have not responded to treatment with sertraline.
What is the current status of trial NCT00282828?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 397 participants. The study started on 2006-03. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00282828?
The interventions under investigation include: Placebo (DRUG), Sertraline (DRUG), Clonazepam (DRUG), Venlafaxine (DRUG).
Who is sponsoring clinical trial NCT00282828?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00282828's enrollment target sits among peer trials
397 218th of 2000 higher than 1,783 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00601939 · 397 participants · NA
Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships
- NCT04115254 · 397 participants · NA
Stereotactic Magnetic Resonance Guided Radiation Therapy
- NCT05365581 · 398 participants · Phase 1
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- NCT05633615 · 396 participants · Phase 2
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia